Aeterna Zentaris

Canaccord Genuity is pleased to announce that on March 11, 2015, it completed an underwritten public offering of common shares and warrants for Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ). Aeterna Zentaris issued a total of 59,677,420 units, raising net proceeds of approximately US$34.5 million. Each unit consists of one common share, 0.75 of a Series A warrant to purchase one common share, and 0.50 of a Series B warrant to purchase one common share, at a purchase price of US$0.62 per unit. Canaccord Genuity acted as sole book-running manager for the offering.

Aeterna Zentaris intends to use the net proceeds from the offering to make the cash payment to the holders of warrants in connection with the warrant amendment agreement, to continue to fund ongoing drug development activities, for the potential addition of commercialized products to its pipeline and for general corporate purposes.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology and endocrinology.  The Company’s product candidates include Macrilen™(macimorelin), an orphan drug that evaluates growth hormone deficiency in adults, and zoptarelin doxorubicin, a targeted therapy for endometrial cancer and other cancers. Aeterna Zentaris is also investigating various additional compounds as potential treatments for a host of unmet medical needs as it works concurrently to pursue strategic initiatives in connection with its goal to become a commercially operating specialty biopharmaceutical company. Aeterna Zentaris is headquartered in Québec City, Canada.